Article
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
The Journal of clinical investigation - 1 Sept 2016
Guignabert Christophe, Phan Carole, Seferian Andrei, Huertas Alice, Tu Ly, Thuillet Raphaël, Sattler Caroline, Le Hiress Morane, Tamura Yuichi, Jutant Etienne-Marie, Chaumais Marie-Camille, Bouchet Stéphane, Manéglier Benjamin, Molimard Mathieu, Rousselot Philippe, Sitbon Olivier, Simonneau Gérald, Montani David, Humbert Marc
Abstract excerpt
Pulmonary arterial hypertension (PAH) is a life-threatening disease that can be induced by dasatinib, a dual Src and BCR-ABL tyrosine kinase inhibitor that is used to treat chronic myelogenous leukemia (CML). Today, key questions remain regarding the mechanisms involved in the long-term development of dasatinib-induced PAH. Here, we demonstrated that chronic dasatinib therapy causes pulmonary endothelial damage...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.